{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:05:53Z","timestamp":1790370353534,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"EXECUTIVE SUMMARY<\/jats:title>\n \n Background<\/jats:title>\n \n Buruli ulcer (BU) disease is a chronic ulcerative skin disease caused by\n Mycobacterium ulcerans<\/jats:italic>\n , which can lead to extensive destruction of the skin, soft tissues and occasionally of bones. Although several antibiotics have demonstrated bactericidal activity against\n M. ulcerans in vitro<\/jats:italic>\n , no consensus on their clinical efficacy against\n M. ulcerans<\/jats:italic>\n in humans has been reached.\n <\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n The objective of the systematic review was to examine the clinical effectiveness of various antibiotic regimens for the treatment of BUs.<\/jats:p>\n <\/jats:sec>\n \n Inclusion criteria Types of participants<\/jats:title>\n The current review considered trials that included patients of all ages with BUs.<\/jats:p>\n <\/jats:sec>\n \n Types of intervention(s)<\/jats:title>\n The current review considered trials that evaluated antibiotic regimens compared to no antibiotics or surgery in patients with BUs.<\/jats:p>\n <\/jats:sec>\n \n Types of studies<\/jats:title>\n The current review considered randomized and non-randomized controlled trials (RCTs). In the absence of RCTs, other research designs such as before and after trials and clinical trials with only an intervention arm were considered for inclusion in a narrative summary.<\/jats:p>\n <\/jats:sec>\n \n Outcomes<\/jats:title>\n The primary outcome of interest were the treatment success rates among the various antibiotics used. Secondary outcomes included changes in lesion size, recurrence of ulcers and incidence of adverse events.<\/jats:p>\n <\/jats:sec>\n \n Search strategy<\/jats:title>\n The search strategy aimed to find both published and unpublished trials. A three-step search strategy was utilized in this review and included English language trials published after 1990. A search across the major databases was conducted up to December 2014.<\/jats:p>\n <\/jats:sec>\n \n Methodological quality<\/jats:title>\n Using the Joanna Briggs Institute (JBI) standardized appraisal tool, two reviewers independently assessed the methodological quality of the trials. A third independent reviewer was available to appraise trials if the two original reviewers disagreed in their assessments. There were no disagreements in findings between the two independent reviewers.<\/jats:p>\n <\/jats:sec>\n \n Data extraction<\/jats:title>\n Data were extracted using the standardized JBI data extraction instruments.<\/jats:p>\n <\/jats:sec>\n \n Data synthesis<\/jats:title>\n Statistical pooling was not possible due to heterogeneity, hence results have been presented in the narrative form.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Seven studies involving a total of 712 patients were included in the final review. Higher treatment success rates ranging from 96% to 100% at the six months follow-up were reported among patients treated with rifampicin-streptomycin for eight weeks (RS8) in two studies. Treatment success with rifampicin-streptomycin for 12 weeks, with surgery at the 12 weeks follow-up, was 91%. In the two studies that investigated the effect of rifampicin-streptomycin for two weeks followed by rifampicin-clarithromycin for six weeks and rifampicin-streptomycin for four weeks followed by rifampicin-clarithromycin for four weeks, treatment success was reported to be 93% and 91%, respectively, at the 12 months follow-up. A significant decrease in the median lesion size at the eight weeks follow-up was reported in patients who were treated with RS8, and a 10-30% decrease in lesion size was reported in those treated with RS12 at the four weeks follow-up.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Treatment success and reduction in lesion size were higher in patients treated with RS8 in the only RCT that compared rifampicin-streptomycin for four weeks followed by rifampicin-clarithromycin for six weeks to RS8, and there was no difference in outcomes, which indicates that local preferences could dictate the treatment option. Evidence obtained from this systematic review indicates that surgery will remain necessary for some ulcers; however, detection of early lesions and treatment with antibiotics would have a greater impact on the control of\n M. ulcerans<\/jats:italic>\n disease. Further large multicenter RCTs investigating the type and optimal duration of oral antibiotic treatment for patients with\n M. ulcerans<\/jats:italic>\n disease are urgently needed.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.11124\/jbisrir-2016-003235","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T16:58:34Z","timestamp":1484326714000},"page":"119-139","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review"],"prefix":"10.11124","volume":"15","author":[{"given":"Asahngwa","family":"Tanywe","sequence":"first","affiliation":[{"name":"The Cameroon Centre for Evidence Based Health Care: a Joanna Briggs Institute Centre of Excellence, Yaounde, Cameroon, Africa"},{"name":"Centre for Behavioral and Social Research, Yaounde, Cameroon, Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritin S.","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Centre for Evidence Based Initiatives in Health Care: a Joanna Briggs Institute Centre of Excellence, University of Wollongong, Wollongong, New South Wales, Australia"},{"name":"St George Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"1","key":"R1-20230825","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/IAI.72.1.62-65.2004","article-title":"Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease","volume":"72","author":"Portaels","year":"2004","journal-title":"Infect Immun"},{"issue":"6","key":"R3-20230825","first-page":"471","article-title":"Une affection m\u00e9connue au Cameroun, l\u2019ulc\u00e8re \u00e0 Mycobact\u00e9rie","volume":"35","author":"Ravisse","year":"1975","journal-title":"Med Trop (Mars)"},{"issue":"5403","key":"R4-20230825","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.283.5403.854","article-title":"Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence","volume":"283","author":"George","year":"1999","journal-title":"Science"},{"issue":"2","key":"R5-20230825","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1128\/IAI.68.2.877-883.2000","article-title":"A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells","volume":"68","author":"George","year":"2000","journal-title":"Infect Immun"},{"issue":"5","key":"R6-20230825","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/archderm.1974.01630110073023","article-title":"Toxin of Mycobacterium ulcerans. Production and effects in guinea pig skin","volume":"110","author":"Krieg","year":"1974","journal-title":"Arch Dermatol"},{"issue":"8","key":"R7-20230825","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1128\/AAC.42.8.2070","article-title":"In vitro susceptibility of Mycobacterium ulcerans to clarithromycin","volume":"42","author":"Portaels","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"R8-20230825","doi-asserted-by":"crossref","first-page":"e0004005","DOI":"10.1371\/journal.pntd.0004005","article-title":"Clinical Epidemiology of Buruli Ulcer from Benin (2005-2013): effect of time-delay to diagnosis on clinical forms and severe phenotypes","volume":"9","author":"Capela","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"R9-20230825","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1590\/S0365-05962010000300002","article-title":"Buruli ulcer","volume":"85","author":"Boleira","year":"2010","journal-title":"An Bras Dermatol"},{"issue":"9","key":"R10-20230825","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/AAC.00299-10","article-title":"Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease","volume":"54","author":"Sarfo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"995","key":"R12-20230825","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/207417a0","article-title":"Effect of rifamycin on protein synthesis","volume":"207","author":"Calvori","year":"1965","journal-title":"Nature"},{"issue":"11","key":"R13-20230825","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1128\/AAC.00175-07","article-title":"Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)","volume":"51","author":"Chauty","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"R14-20230825","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1128\/AAC.49.8.3182-3186.2005","article-title":"Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans","volume":"49","author":"Etuaful","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"9715","key":"R15-20230825","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0140-6736(09)61962-0","article-title":"Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial","volume":"375","author":"Nienhuis","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"R16-20230825","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1128\/AAC.03763-14","article-title":"Compliance with antimicrobial therapy for Buruli ulcer","volume":"58","author":"Klis","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"R17-20230825","doi-asserted-by":"crossref","first-page":"e2739","DOI":"10.1371\/journal.pntd.0002739","article-title":"Long term streptomycin toxicity in the treatment of Buruli ulcer: follow-up of participants in the BURULICO drug trial","volume":"8","author":"Klis","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"R18-20230825","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1128\/AAC.02165-13","article-title":"Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease","volume":"58","author":"Phillips","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"R19-20230825","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/jac\/45.2.231","article-title":"In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans","volume":"45","author":"Thangaraj","year":"2000","journal-title":"J Antimicrob Chemother"},{"issue":"8723","key":"R20-20230825","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0140-6736(90)92581-2","article-title":"Buruli ulcer in Benin","volume":"336","author":"Muelder","year":"1990","journal-title":"Lancet"},{"issue":"5","key":"R21-20230825","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S1473-3099(06)70464-9","article-title":"Mycobacterium ulcerans infection: control, diagnosis, and treatment","volume":"6","author":"Sizaire","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"R22-20230825","first-page":"785","article-title":"Mycobacterium ulcerans disease","volume":"83","author":"Van der Werf","year":"2005","journal-title":"Bull World Health Organ"},{"issue":"8","key":"R23-20230825","first-page":"1","article-title":"The effectiveness of treatment of Buruli ulcer with streptomycin-rifampicin: a systematic review","volume":"7","author":"Constantine","year":"2009","journal-title":"JBI Database System Rev Implement Rep"},{"issue":"1","key":"R24-20230825","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1128\/CVI.00235-08","article-title":"Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans","volume":"16","author":"Sarfo","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"7","key":"R25-20230825","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1371\/journal.pntd.0000736","article-title":"Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli ulcer (Mycobacterium ulcerans disease)","volume":"4","author":"Kibadi","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"R26-20230825","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1042\/BST20130133","article-title":"Pleiotropic molecular effects of the Mycobacterium ulcerans virulence factor mycolactone underlying the cell death and immunosuppression seen in Buruli ulcer","volume":"42","author":"Hall","year":"2014","journal-title":"Biochem Soc Trans"},{"issue":"8","key":"R27-20230825","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5694\/mja12.11559","article-title":"Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy","volume":"198","author":"Trevillyan","year":"2013","journal-title":"Med J Aust"},{"issue":"4","key":"R28-20230825","doi-asserted-by":"crossref","first-page":"e2809","DOI":"10.1371\/journal.pntd.0002809","article-title":"Immunohistochemical monitoring of wound healing in antibiotic treated Buruli ulcer patients","volume":"8","author":"Andreoli","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"R29-20230825","doi-asserted-by":"crossref","first-page":"e36954","DOI":"10.1371\/journal.pone.0036954","article-title":"What role do traditional beliefs play in treatment seeking and delay for Buruli ulcer disease? \u2013 insights from a mixed methods study in Cameroon","volume":"7","author":"Grietens","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"R30-20230825","first-page":"1","article-title":"Burden of Buruli ulcer: how affected households in a Ghanaian District Cope","volume":"32","author":"Adamba","year":"2011","journal-title":"African Study Monographs"}],"container-title":["JBI Database of Systematic Reviews and Implementation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01938924-201701000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:56:45Z","timestamp":1786453005000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01938924-201701000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.11124\/jbisrir-2016-003235","relation":{},"ISSN":["2202-4433"],"issn-type":[{"value":"2202-4433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}